PURPOSE: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin. STUDY DESIGN: Patients were treated with doxorubicin intravenously (IV) on day 1 and Triapine IV on days 1-4 of a 21-day cycle. The starting dose (level 1) was doxorubicin 60 mg/m(2) and Triapine 25 mg/m(2). PK analysis was performed at various time-points before and after treatment. RESULTS: Twenty patients received a total of 49 courses of treatment on study. At dose level 2 (doxorubicin 60 mg/m(2), Triapine 45 mg/m(2)), two patients experienced DLTs (febrile neutropenia, grade 4 thrombocytopenia). An additional three patients were enrolled at dose level 1 without initial toxicity. Enrollment then resumed at dose level 2a with a decreased dose of doxorubicin (45 mg/m(2)) with Triapine 45 mg/m(2). The two patients enrolled on this level had two DLTs (diarrhea, CVA). Enrollment was planned to resume at dose level 1; however, the sixth patient enrolled to this cohort developed grade 5 heart failure (ejection fraction 20%, pretreatment EF 62%) after the second course. Thus, doxorubicin and Triapine were reduced to 45 and 25 mg/m(2), respectively (level 1a), prior to resuming enrollment at dose level 1, the MTD. The main drug-related toxicity was myelosuppression. Non-hematologic toxicities included mild-to-moderate fatigue, grade 3 diarrhea and grade 4 CVA. There was one treatment-related death due to heart failure. While no objective responses were observed, subjective evidence of clinical activity was observed in patients with refractory melanoma and prostate cancer. CONCLUSIONS: Pretreated patients with advanced malignancies can tolerate the combination of Triapine and doxorubicin at doses that achieve subjective clinical benefit with the main treatment-related toxicities being myelosuppression and fatigue. The MTD was determined to be doxorubicin 60 mg/m(2) on day 1 and Triapine 25 mg/m(2) on days 1-4 of a 21-day cycle.
PURPOSE: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin. STUDY DESIGN:Patients were treated with doxorubicin intravenously (IV) on day 1 and Triapine IV on days 1-4 of a 21-day cycle. The starting dose (level 1) was doxorubicin 60 mg/m(2) and Triapine 25 mg/m(2). PK analysis was performed at various time-points before and after treatment. RESULTS: Twenty patients received a total of 49 courses of treatment on study. At dose level 2 (doxorubicin 60 mg/m(2), Triapine 45 mg/m(2)), two patients experienced DLTs (febrile neutropenia, grade 4 thrombocytopenia). An additional three patients were enrolled at dose level 1 without initial toxicity. Enrollment then resumed at dose level 2a with a decreased dose of doxorubicin (45 mg/m(2)) with Triapine 45 mg/m(2). The two patients enrolled on this level had two DLTs (diarrhea, CVA). Enrollment was planned to resume at dose level 1; however, the sixth patient enrolled to this cohort developed grade 5 heart failure (ejection fraction 20%, pretreatment EF 62%) after the second course. Thus, doxorubicin and Triapine were reduced to 45 and 25 mg/m(2), respectively (level 1a), prior to resuming enrollment at dose level 1, the MTD. The main drug-related toxicity was myelosuppression. Non-hematologic toxicities included mild-to-moderate fatigue, grade 3 diarrhea and grade 4 CVA. There was one treatment-related death due to heart failure. While no objective responses were observed, subjective evidence of clinical activity was observed in patients with refractory melanoma and prostate cancer. CONCLUSIONS: Pretreated patients with advanced malignancies can tolerate the combination of Triapine and doxorubicin at doses that achieve subjective clinical benefit with the main treatment-related toxicities being myelosuppression and fatigue. The MTD was determined to be doxorubicin 60 mg/m(2) on day 1 and Triapine 25 mg/m(2) on days 1-4 of a 21-day cycle.
Authors: Eric H Rubin; Dinesh P de Alwis; Isabelle Pouliquen; Lisa Green; Phil Marder; Yong Lin; Rita Musanti; Stephanie L Grospe; Sharon L Smith; Deborah L Toppmeyer; Judy Much; Michael Kane; Ajai Chaudhary; Christopher Jordan; Michael Burgess; Christopher A Slapak Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: R A Finch; M Liu; S P Grill; W C Rose; R Loomis; K M Vasquez; Y Cheng; A C Sartorelli Journal: Biochem Pharmacol Date: 2000-04-15 Impact factor: 5.858
Authors: John Murren; Manuel Modiano; Caroline Clairmont; Paula Lambert; Niramol Savaraj; Terry Doyle; Mario Sznol Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: Francis J Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi Journal: Leuk Res Date: 2003-12 Impact factor: 3.156
Authors: Jill Kolesar; Richard C Brundage; Marcia Pomplun; Dona Alberti; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding Journal: Cancer Chemother Pharmacol Date: 2010-05-04 Impact factor: 3.333
Authors: Hongxia Lin; Xin Yu; Oliver S Eng; Brian Buckley; Ah-Ng Tony Kong; Joseph R Bertino; Darren R Carpizo; Murugesan K Gounder Journal: Biomed Chromatogr Date: 2015-05-05 Impact factor: 1.902
Authors: Jill M Kolesar; Kamakshi Sachidanandam; William R Schelman; Jens Eickhoff; Kyle D Holen; Anne M Traynor; Dona B Alberti; James P Thomas; Christopher R Chitambar; George Wilding; William E Antholine Journal: Exp Ther Med Date: 2011-01 Impact factor: 2.447
Authors: Brian S Choi; Dona B Alberti; William R Schelman; Jill M Kolesar; James P Thomas; Rebecca Marnocha; Jens C Eickhoff; S Percy Ivy; George Wilding; Kyle D Holen Journal: Cancer Chemother Pharmacol Date: 2010-02-02 Impact factor: 3.333
Authors: Charles Kunos; Tomas Radivoyevitch; Fadi W Abdul-Karim; James Fanning; Ovadia Abulafia; Albert J Bonebrake; Lydia Usha Journal: J Transl Med Date: 2012-04-27 Impact factor: 5.531
Authors: Maida De Bortoli; Elena Taverna; Elisa Maffioli; Patrizia Casalini; Francesco Crisafi; Vikas Kumar; Claudio Caccia; Dario Polli; Gabriella Tedeschi; Italia Bongarzone Journal: J Exp Clin Cancer Res Date: 2018-04-03